David H Lovett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10818108/publications.pdf

Version: 2024-02-01

73 papers	3,992 citations	109321 35 h-index	118850 62 g-index
73 all docs	73 docs citations	73 times ranked	4057 citing authors

#	Article	IF	Citations
1	Gelatinase A (MMP-2) Is Necessary and Sufficient for Renal Tubular Cell Epithelial-Mesenchymal Transformation. American Journal of Pathology, 2003, 162, 1937-1949.	3.8	232
2	Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB Journal, 2006, 20, 1898-1900.	0.5	212
3	Discoidin Domain Receptor 2 Regulates Fibroblast Proliferation and Migration through the Extracellular Matrix in Association with Transcriptional Activation of Matrix Metalloproteinase-2. Journal of Biological Chemistry, 2002, 277, 3606-3613.	3.4	205
4	A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochemical Journal, 2003, 369, 485-496.	3.7	189
5	Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1847-H1860.	3.2	161
6	Proteinases and glomerular matrix turnover. Kidney International, 1992, 41, 671-678.	5.2	148
7	Matrix Metalloproteinase 2 (Gelatinase A) Regulates Glomerular Mesangial Cell Proliferation and Differentiation. Journal of Biological Chemistry, 1996, 271, 15074-15083.	3.4	142
8	Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney International, 1983, 23, 342-349.	5.2	141
9	Glomerular Mesangial Cell-specific Transactivation of Matrix Metalloproteinase 2 Transcription Is Mediated by YB-1. Journal of Biological Chemistry, 1997, 272, 22905-22912.	3.4	136
10	A Synergistic Interaction of Transcription Factors AP2 and YB-1 Regulates Gelatinase A Enhancer-dependent Transcription. Journal of Biological Chemistry, 1998, 273, 32957-32965.	3.4	99
11	Cell culture approaches to the analysis of glomerular inflammation. Kidney International, 1986, 30, 246-254.	5.2	98
12	A Novel Intracellular Isoform of Matrix Metalloproteinase-2 Induced by Oxidative Stress Activates Innate Immunity. PLoS ONE, 2012, 7, e34177.	2.5	94
13	Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1838-H1846.	3.2	91
14	Tissue-specific Enhancer-Promoter Interactions Regulate High Level Constitutive Expression of Matrix Metalloproteinase 2 by Glomerular Mesangial Cells. Journal of Biological Chemistry, 1995, 270, 18786-18796.	3.4	88
15	Interleukin 1: The patterns of translation and intracellular distribution support alternative secretory mechanisms. Journal of Cellular Physiology, 1992, 152, 223-231.	4.1	82
16	Human mesangial cells secrete a GBM-degrading neutral proteinase and a specific inhibitor. Kidney International, 1989, 36, 790-801.	5.2	79
17	Transcription Factor YB-1 Mediates DNA Polymerase Î± Gene Expression. Journal of Biological Chemistry, 2005, 280, 7702-7711.	3.4	77
18	Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovascular Research, 2006, 69, 688-696.	3.8	75

#	Article	IF	Citations
19	Linked Common Polymorphisms in the Gelatinase A Promoter Are Associated with Diminished Transcriptional Response to Estrogen and Genetic Fitness. Journal of Biological Chemistry, 2003, 278, 20490-20499.	3.4	71
20	Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2216-H2228.	3.2	71
21	Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. Journal of Orthopaedic Research, 2012, 30, 1440-1446.	2.3	67
22	Insulin and Insulin-Like Growth Factor I Binding to Cultured Rat Glomerular Mesangial Cells*. Endocrinology, 1988, 123, 2432-2439.	2.8	66
23	The prodomain of interleukin 1Î± interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB Journal, 2003, 17, 203-213.	0.5	65
24	mTOR regulates fatty infiltration through SREBPâ€1 and PPARÎ³ after a combined massive rotator cuff tear and suprascapular nerve injury in rats. Journal of Orthopaedic Research, 2013, 31, 724-730.	2.3	63
25	Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochemical and Biophysical Research Communications, 2007, 358, 189-195.	2.1	61
26	Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16345-16350.	7.1	58
27	Combinatorial Interactions of p53, Activating Protein-2, and YB-1 with a Single Enhancer Element Regulate Gelatinase A Expression in Neoplastic Cells. Journal of Biological Chemistry, 2002, 277, 24875-24882.	3.4	56
28	Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochemical Journal, 2004, 380, 735-747.	3.7	51
29	N-Terminal Truncated Intracellular Matrix Metalloproteinase-2 Induces Cardiomyocyte Hypertrophy, Inflammation and Systolic Heart Failure. PLoS ONE, 2013, 8, e68154.	2.5	47
30	Tumour metastasis suppressor, nm23-Î², inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). Biochemical Journal, 2002, 366, 807-816.	3.7	46
31	The disintegrin domain of ADAM9: a ligand for multiple Î²1 renal integrins. Biochemical Journal, 2005, 385, 461-468.	3.7	44
32	YB-1 Regulation of the Human and Rat Gelatinase A Genes via Similar Enhancer Elements. Journal of the American Society of Nephrology: JASN, 1999, 10, 2480-2487.	6.1	44
33	YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochemical and Biophysical Research Communications, 2010, 398, 482-488.	2.1	43
34	Interleukin 1 and the glomerular mesangium. III. IL-1-dependent stimulation of mesangial cell protein kinase activity. Kidney International, 1988, 34, 26-35.	5.2	42
35	Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Developmental Dynamics, 1998, 213, 121-129.	1.8	39
36	Regulation of MMP-2 Gene Transcription in Dermal Wounds. Journal of Investigative Dermatology, 2007, 127, 1762-1767.	0.7	36

#	Article	IF	Citations
37	Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. Physiological Reports, 2017, 5, e13305.	1.7	36
38	Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney International, 2005, 68, 278-284.	5.2	34
39	Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney International, 1997, 51, 1397-1400.	5.2	33
40	Transcription Factor Ets-1 Regulates Gelatinase A Gene Expression in Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2002, 13, 1568-1578.	6.1	33
41	Pharmacological inhibition of gelatinase B induction and tumor cell invasion. , 1996, 67, 523-531.		31
42	Associations of interleukinâ€6, Câ€reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology, 2008, 13, 593-600.	1.6	29
43	Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovascular Pathology, 2009, 18, 253-261.	1.6	29
44	Intraventricular and interventricular cellular heterogeneity of inotropic responses to Î±₁-adrenergic stimulation. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H946-H953.	3.2	29
45	Asymmetric origins of the mature glomerular basement membrane. Journal of Cellular Physiology, 1993, 157, 169-177.	4.1	26
46	Polymeric meshes induce zonal regulation of matrix metalloproteinaseâ€2 gene expression by macrophages and fibroblasts. FASEB Journal, 2007, 21, 1047-1057.	0.5	25
47	Identification, Cellular Distribution and Potential Function of the Metalloprotease-Disintegrin MDC9 in the Kidney. Journal of the American Society of Nephrology: JASN, 2000, 11, 595-603.	6.1	25
48	Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. Journal of Vascular Surgery, 2005, 42, 539-545.	1.1	24
49	A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Frontiers in Physiology, 2014, 5, 363.	2.8	23
50	Telomerase Deficiency in Bone Marrowâ€“Derived Cells Attenuates Angiotensin IIâ€“Induced Abdominal Aortic Aneurysm Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 253-260.	2.4	20
51	Î±_{1A}-Subtype adrenergic agonist therapy for the failing right ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H1109-H1118.	3.2	19
52	Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. International Journal of Experimental Pathology, 2011, 92, 50-56.	1.3	18
53	Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy. PLoS ONE, 2017, 12, e0171625.	2.5	18
54	Myofilament dysfunction contributes to impaired myocardial contraction in the infarct border zone. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1150-H1158.	3.2	17

#	Article	IF	Citations
55	The Hematopoietic Transcription Factor PU.1 Represses Gelatinase A Transcription in Glomerular Mesangial Cells. Journal of Biological Chemistry, 2000, 275, 19552-19559.	3.4	16
56	Expression of a G_i-coupled receptor in the heart causes impaired Ca²⁺handling, myofilament injury, and dilated cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H205-H212.	3.2	16
57	Enhanced cardiac expression of two isoforms of matrix metalloproteinase-2 in experimental diabetes mellitus. PLoS ONE, 2019, 14, e0221798.	2.5	16
58	Myocardial injection of a thermoresponsive hydrogel with reactive oxygen species scavenger properties improves border zone contractility. Journal of Biomedical Materials Research - Part A, 2020, 108, 1736-1746.	4.0	16
59	Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochemical and Biophysical Research Communications, 2010, 396, 219-223.	2.1	15
60	Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis. Journal of Cardiovascular Pharmacology, 2016, 67, 47-56.	1.9	15
61	An intracellular matrix metalloproteinase-2 isoform induces tubular regulated necrosis: implications for acute kidney injury. American Journal of Physiology - Renal Physiology, 2017, 312, F1166-F1183.	2.7	14
62	Short term doxycycline treatment induces sustained improvement in myocardial infarction border zone contractility. PLoS ONE, 2018, 13, e0192720.	2.5	13
63	Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. Reproductive Biology and Endocrinology, 2009, 7, 41.	3.3	12
64	Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles, Ligaments and Tendons Journal, 2013, 3, 35-41.	0.3	12
65	Two Distinct Isoforms of Matrix Metalloproteinase-2 Are Associated with Human Delayed Kidney Graft Function. PLoS ONE, 2015, 10, e0136276.	2.5	12
66	Matrix metalloproteinase-2 plays a critical role in overload induced skeletal muscle hypertrophy. Muscles, Ligaments and Tendons Journal, 2014, 4, 446-54.	0.3	12
67	Reversal of right ventricular failure by chronic Î±_{1A}-subtype adrenergic agonist therapy. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H224-H232.	3.2	10
68	Nonsurgical Periodontal Therapy in CKD: Findings of the Kidney and Periodontal Disease (KAPD) Pilot Randomized Controlled Trial. Kidney Medicine, 2020, 2, 49-58.	2.0	7
69	The expression of two isoforms of matrix metalloproteinase-2 in aged mouse models of diabetes mellitus and chronic kidney disease. Kidney Research and Clinical Practice, 2018, 37, 222-229.	2.2	6
70	Matrix metalloproteinase-2 plays a critical role in overload induced skeletal muscle hypertrophy. Muscles, Ligaments and Tendons Journal, 2014, 4, 362-70.	0.3	4
71	Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype. Carcinogenesis, 2011, 32, 1806-1814.	2.8	3
72	The two isoforms of matrix metalloproteinase- 2 have distinct renal spatial and temporal distributions in murine models of types 1 and 2 diabetes mellitus. BMC Nephrology, 2018, 19, 248.	1.8	3

#	Article	IF	Citations
73	Novel intracellular Nâ€terminal truncated matrix metalloproteinaseâ€2 isoform in skeletal muscle ischemiaâ€reperfusion injury. Journal of Orthopaedic Research, 2016, 34, 502-509.	2.3	2